UC San Diego researchers discovered that people with an inactive RNA-editing enzyme respond better to cancer immunotherapy, and inhibitors of the enzyme help mice with difficult-to-treat cancers live longer.
Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers.
Researchers at UC San Diego School of Medicine are among the contributors to a package of 10 studies in the journal Nature, describing the latest results from the ongoing Encyclopedia of DNA Elements project, a worldwide effort led by the NIH to understand how the human genome functions.
By analyzing the FDA database of adverse drug effects, UC San Diego researchers discovered that people who received Botox injections — not just in the forehead — reported depression significantly less often than patients undergoing different treatments for the same conditions.
For the 20th consecutive year, U.S. News & World Report has recognized UCI Medical Center as one of America’s Best Hospitals. The annual rankings recognize hospitals that excel in treating the most challenging patients and conditions. This year, the report highlights the excellence of UCI Health programs in gynecology, No…
UC San Diego Health is ranked first in San Diego and sixth in California, placing it among the nation’s best hospitals, according to the 2020-2021 U.S. News and World Report. Eight common procedures and conditions were also rated “high performing.”
Researchers at Ludwig Institute for Cancer Research and University of California San Diego School of Medicine report that inhibiting a key enzyme caused human cancer cells associated with two major types of breast and ovarian cancer to die and in mouse studies reduced tumor growth.
UC San Diego Health is ranked first in San Diego and sixth in California, placing it among the nation’s best hospitals, according to the 2020-2021 U.S. News & World Report. The annual rankings are designed to assist patients and their doctors in making informed decisions about where to...
UC San Diego Health and the Altman Clinical and Translational Research Institute will be sites for an accelerated national clinical trial to assess the efficacy and immunogenicity of a vaccine intended to protect against SARS-CoV-2, the coronavirus that causes COVID-19.
Health Media Contacts
Find the best contact for health-related media inquiries.
